Target brain: Neuroprotection and neurorestoration in ischemic stroke

Reviews in Neurological Diseases

Volumn 7, Issue SUPPL. 1, 2010, Pages

  Saver, Jeffrey L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Citicoline; Magnesium sulfate; Neuroprotection; Neurorestoration; Stroke

Indexed keywords

CITICOLINE; MAGNESIUM SULFATE; NEUROPROTECTIVE AGENT;

BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; BRAIN INFARCTION; BRAIN ISCHEMIA; CLINICAL TRIAL; EPILEPTIC STATE; HEART ARREST; HUMAN; NERVE CELL PLASTICITY; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PREMATURITY; REVIEW; SUBARACHNOID HEMORRHAGE; ANIMAL; BRAIN; CLINICAL TRIAL (TOPIC); COMPLICATION; DRUG EFFECTS; PATHOLOGY; PATHOPHYSIOLOGY; STROKE; TIME;

ANIMALS; BRAIN; BRAIN ISCHEMIA; CLINICAL TRIALS AS TOPIC; HUMANS; NEURONAL PLASTICITY; NEUROPROTECTIVE AGENTS; STROKE; TIME FACTORS;

EID: 77955646488     PISSN: 15452913     EISSN: None     Source Type: Journal    
DOI: 10.3909/rind7S1S0003     Document Type: Review

References (26)

1. Ovbiagele B, Kidwell CS, Starkman S, Saver JL. Neuroprotective agents for the treatment of acute ischemic stroke. Curr Neurol Neurosci Rep. 2003;3:9-20. (Pubitemid 38898978)
2. Ginsberg MD. Current status of neuroprotection for cerebral ischemia: synoptic overview. Stroke. 2009;40:S111-S114.
3. Kidwell CS, Liebeskind DS, Starkman S, Saver JL. Trends in acute ischemic stroke trials through the 20th century. Stroke. 2001;32:1349-1359. (Pubitemid 32530421)
4. Donnan GA. The 2007 Feinberg lecture: a new road map for neuroprotection. Stroke. 2008; 39:242.
5. Ferguson KN, Kidwell CS, Starkman S, Saver JL. Hyperacute treatment initiation in neuroprotective agent stroke trials. J Stroke Cerebrovasc Dis. 2004;13:109-112. (Pubitemid 38885683)
6. Bernard SA, Gray TW, Buist MD, et al. Treatment of comatose survivors of out-of-hospital cardiac arrest with induced hypothermia. N Engl J Med. 2002;346:557-563. (Pubitemid 34438816)
7. Muir KW. Therapeutic potential of magnesium in the treatment of acute stroke. J Stroke Cerebrovasc Dis. 2000;9:257-267.
8. Longstreth WT Jr, Fahrenbruch CE, Olsufka M, et al. Randomized clinical trial of magnesium, diazepam, or both after out-of-hospital cardiac arrest. Neurology. 2002;59:506-514. (Pubitemid 34919982)
9. Crowther CA, Hiller JE, Doyle LW, Haslam RR. Effect of magnesium sulfate given for neuroprotection before preterm birth: a randomized controlled trial. JAMA. 2003;290:2669-2676.
10. Bhudia SK, Cosgrove DM, Naugle RI, et al. Magnesium as a neuroprotectant in cardiac surgery: a randomized clinical trial. J Thorac Cardiovasc Surg. 2006;131:853-861.
11. van den Bergh WM, Algra A, van Kooten F, et al. Magnesium sulfate in aneurysmal subarachnoid hemorrhage: a randomized controlled trial. Stroke. 2005;36:1011-1015. (Pubitemid 40629294)
12. Muir KW, Lees KR, Ford I, Davis S; Intravenous Magnesium Efficacy in Stroke (IMAGES) Study Investigators. Magnesium for acute stroke (Intravenous Magnesium Efficacy in Stroke trial): randomised controlled trial. Lancet. 2004;363:439-445.
13. Saver JL, Kidwell C, Eckstein M, Starkman S; FAST-MAG Pilot Trial Investigators. Prehospital neuroprotective therapy for acute stroke: results of the Field Administration of Stroke Therapy-Magnesium (FAST-MAG) pilot trial. Stroke. 2004;35:e106-e108.
14. Llanes JN, Kidwell CS, Starkman S, et al. The Los Angeles Motor Scale (LAMS): a new measure to characterize stroke severity in the field. Prehosp Emerg Care. 2004;8:46-50. (Pubitemid 38049892)
15. Sanossian N, Starkman S, Liebeskind DS, et al; FAST-MAG Trial Investigators. Simultaneous ring voice-over-internet phone system enables rapid physician elicitation of explicit informed consent in prehospital stroke treatment trials. Cerebrovasc Dis. 2009;28:539-544.
16. Saver JL, Eckstein M, Stratton SJ, et al; FAST-MAG Trial Investigators. The field administration of stroke therapy-magnesium (FAST-MAG) phase 3 trial. Paper presented at: International Stroke Conference: Ongoing Clinical Trials Poster Session; February 24-26, 2010; San Antonio, TX.
17. Gutiérrez M, Merino JJ, de Leciñana MA, Díez- Tejedor E. Cerebral protection, brain repair, plasticity and cell therapy in ischemic stroke. Cerebrovasc Dis. 2009;27(suppl 1):177-186.
18. Birbaumer N, Murguialday AR, Cohen L. Brain-computer interface in paralysis. Curr Opin Neurol. 2008;21:634-638.
19. Secades JJ, Lorenzo JL. Citicoline: pharmacological and clinical review, 2006 update. Methods Find Exp Clin Pharmacol. 2006; 28(suppl B):1-56.
20. Saver JL. Citicoline: update on a promising and widely available agent for neuroprotection and neurorepair. Rev Neurol Dis. 2008;5:167-177.
21. Hurtado O, Cárdenas A, Pradillo JM, et al. A chronic treatment with CDP-choline improves functional recovery and increases neuronal plasticity after experimental stroke. Neurobiol Dis. 2007;26:105-111. (Pubitemid 46436490)
22. Rema V, Bali KK, Ramachandra R, et al. Cytidine-5-diphosphocholine supplement in early life induces stable increase in dendritic complexity of neurons in the somatosensory cortex of adult rats. Neuroscience. 2008;155:556-564.
23. Warach SM, Harnett K. Predictive validity of MRI as a surrogate endpoint in stroke trials: change in lesion volume predicts clinical outcome [abstract]. Stroke. 2002;33:356.
24. Warach S, Pettigrew LC, Dashe JF, et al. Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Citicoline 010 investigators. Ann Neurol. 2000;48:713-722.
25. Álvarez-Sabín J, Jacas C, Ortega G, et al. [Citicoline influence in cognitive decline after first ischemic stroke.] Paper presented at: XII Congreso de la Sociedad Iberoamericana de Enfermedad Cerebro Vascular; September 2-4, 2009; Asunción, Paraguay.
26. Dávalos A. Citicoline. Int J Stroke. 2008; 3(suppl 1):440.